Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from In vitro and In vivo Oncology

  • You have access
    A preclinical study of minibody 177Lu-DOTA-IAB2 targeting PSMA for Radiopharmaceutical Therapy of Prostate Cancer
    Fang Jia, Gareth Smith, Leticia Maria De Souza Cordeiro, Kelley Diaz, Ian Wilson and Alessandro Mascioni
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4027;
  • You have access
    Preliminary evaluation of 131I-labeled ITGA5 inhibitor for targeted radionuclide therapy of pancreatic cancer xenografts
    Tao Wang
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4021;
  • You have access
    Immuno-PET using 89Zr-labeled Glypican-1 antibody: a novel theranostic probe for the antibody-drug conjugate treatment in pancreatic cancer
    Tadashi Watabe, Sadahiro Naka, Satoshi Serada, Eku Shimosegawa and Tetsuji Naka
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4041;
  • You have access
    The journey to a novel theranostic for prostate cancer : the preclinical study of 64Cu-DOTHA2-PSMA
    Marie-Christine Milot, Ophelie Belissant Benesty, Veronique Dumulon-Perreault, Samia Ait-Mohand, Sameh Geha, Patrick Richard, Etienne Rousseau and Brigitte Guerin
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4025;
  • You have access
    Potentiation of Immune Checkpoint Inhibition with Molecular-Targeted Radiation
    Simone Kleinendorst, Peter Chandler, Egbert Oosterwijk, Mark Konijnenberg, Kwame Twumasi-Boateng, Michael Wheatcroft and Sandra Heskamp
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4039;
  • You have access
    Bone marrow RBE for a 212Pb-conjugated anti-HER2/neu antibody
    Ioanna Liatsou, Anders Josefsson, Jing Yu, Angel Cortez, Remco Bastiaannet, Esteban Velarde, Cory Brayton, Hao Wang, Julien Torgue, Robert Hobbs and George Sgouros
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4062;
  • You have access
    Chlorin e6-Loaded Goat Milk-derived Extracellular Vesicles for Cerenkov Luminescence-induced Photodynamic Therapy
    Rong Guo, Yongkang Gai, Dawei Jiang, Xiaoli Lan and Rui An
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4042;
  • You have access
    PET imaging of mesothelioma in mouse models with a clinical stage CD46 targeting human monoclonal antibody
    Jun Li, Yang Su, Ping Chen, Bin Liu and Jiang He
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4046;
  • You have access
    Noninvasive monitoring of treatment response in lung cancer using F-18 labeled Fluorodeoxyglucarate
    Junling Li, Huaiyu Zheng, Alexis Vega, Levi Beverly, Brian Gray, Koon Pak and Chin Ng
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4018;
  • You have access
    Evaluation of receptor-specific radiotracer binding in the HET-CAM model by PET-MRI with inhibition studies
    Jessica Loeffler, Carmen Hamp, Christoph Solbach, Mareike Wirth, Gerhard Glatting, Volker Rasche, Ambros Beer and Gordon Winter
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4034;

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
SNMMI

© 2025 SNMMI

Powered by HighWire